Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,957.50    33.00 (1.71%)
Bid:
1,961.00
Ask:
1,961.50
Spread: 0.50 (0.025%)
Market Cap: £78.45b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

19 Aug 2025 15:30

RNS Number : 9066V
GSK PLC
19 August 2025
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$39.3600

3,328.441

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-08-15

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$39.3600

84

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-08-15

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

  

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of notional ADSs within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$39.3600

61.934

d)

Aggregated information

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2025-08-15

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFESAUEISEIA
Date   Source Headline
8th May 20253:30 pmRNSDirector/PDMR Shareholding
8th May 202511:15 amRNSLinerixibat GLISTEN pIII trial data at EASL
8th May 20257:00 amRNSTransaction in Own Shares
7th May 20256:22 pmRNSResult of AGM
7th May 20257:00 amRNSTransaction in Own Shares
6th May 20257:00 amRNSTransaction in Own Shares
2nd May 20257:00 amRNSTransaction in Own Shares
1st May 20253:30 pmRNSDirector/PDMR Shareholding
1st May 20253:00 pmRNSTotal Voting Rights
1st May 20257:00 amRNSNucala MATINEE data in COPD published in NEJM
1st May 20257:00 amRNSTransaction in Own Shares
30th Apr 20257:05 amRNSTransaction in Own Shares
30th Apr 20257:00 amRNS1st Quarter Results
29th Apr 20257:00 amRNSTransaction in Own Shares
28th Apr 20257:00 amRNSTransaction in Own Shares
25th Apr 20257:00 amRNSTransaction in Own Shares
24th Apr 20257:00 amRNSTransaction in Own Shares
23rd Apr 20257:00 amRNSTransaction in Own Shares
22nd Apr 20257:00 amRNSTransaction in Own Shares
17th Apr 20254:13 pmRNSBlenrep licensed by UK MHRA
17th Apr 20253:30 pmRNSDirector/PDMR Shareholding
17th Apr 20257:10 amRNSArexvy now ACIP recommended for 50-59 at risk
17th Apr 20257:05 amRNSGSK 5-in-1 meningitis vaccine recommended in US
17th Apr 20257:00 amRNSTransaction in Own Shares
16th Apr 20257:00 amRNSTransaction in Own Shares
15th Apr 20253:30 pmRNSDirector/PDMR Shareholding
15th Apr 20257:00 amRNSTransaction in Own Shares
14th Apr 20257:00 amRNSTransaction in Own Shares
11th Apr 20253:30 pmRNSDirector/PDMR Shareholding
11th Apr 20257:00 amRNSTransaction in Own Shares
10th Apr 20257:00 amRNSTransaction in Own Shares
9th Apr 20257:00 amRNSTransaction in Own Shares
8th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSTransaction in Own Shares
4th Apr 20257:00 amRNSTransaction in Own Shares
3rd Apr 20257:00 amRNSTransaction in Own Shares
2nd Apr 20257:00 amRNSTransaction in Own Shares
1st Apr 20253:30 pmRNSTotal Voting Rights
1st Apr 20257:00 amRNSTransaction in Own Shares
31st Mar 20257:00 amRNSTransaction in Own Shares
28th Mar 20253:30 pmRNSDirector/PDMR Shareholding
28th Mar 20257:00 amRNSTransaction in Own Shares
27th Mar 20257:00 amRNSTransaction in Own Shares
26th Mar 20257:00 amRNSTransaction in Own Shares
25th Mar 20254:34 pmRNSGSK uUTI treatment approved by US FDA
25th Mar 20257:00 amRNSTransaction in Own Shares
24th Mar 20254:10 pmRNSNotice of AGM
24th Mar 20257:05 amRNSEMA Filing acceptance for Nucala COPD
24th Mar 20257:00 amRNSTransaction in Own Shares
21st Mar 20253:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.